Cervomed Inc CRVO

$1.60 -0.15 (-8.57%)

Valuation

Market cap
24,190,000
Revenue TTM
$4,010,000
Net income TTM
$-26,970,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-672.57%
Debt to equity
0.00

Trading

Volume
585,300
Avg volume
253,858
Day's range
$1.60 – $1.77
Shares out
15,119,000
Stochastic %K
0%
Beta
-0.75
Analysts
Strong Buy
Price target
$18.00

Price

Company profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease...

Show more

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 744 4400
Website
https://www.cervomed.com
Address
20 Park Plaza, Suite 424, Boston, United States

Latest news

Stocktwits

Bottleinthesmoke Nov 1, 2:48 PM
$CRVO Short term we are in trouble and institutions are exiting but why are they exiting? ..Answer is because there is no foreseeable partnership, However here is the KEY .... Management is heavily invested in this because they believe in their product, therefore there might be a big offering diluting the stock for the short term but once financing is secured for phase three trials institutions will buy back in big time. So hold on and don't engage with people that flip nickles and dimes......might be naive but that's my opinion
1 replies
Adorno99 Oct 30, 10:27 PM
$CRVO I think this will have a robust bounce some time in the next few weeks. A lot of people will realize they overreacted to old new that should have already been baked in. And that after falling from 3.20-3.30 the week before that, for apparently no reason. Will buy more next week if this is still hovering near these prices
0 replies
Mfv Oct 30, 7:13 PM
$CRVO Ridiculous. Alam, Boger, and the entire group. Horrible job. On level with Cobuzzi.
0 replies
Doom_Gloom_AR Oct 30, 3:27 PM
$CRVO boger will not give up he believes in this, I think it works too, he will fund it himself, sell the company or partner it, I like this value down here 26m for p3 ready company with decent proof of concept. Plus readouts in ftd & stroke in the near term. My guess has been for a long time now, that they think they are going to work in ftd and/or stroke - the goal here is if one of the two hits the re-rating will allow them to fund the rest of the program. My guess is they are holding in their back pocket a partnership deal where then get a 100m~$250M up front and low teens royalties - should ftd & stroke fail they will take this deal and sell off the shell company.
1 replies
Stu_padasso Oct 30, 1:39 PM
$CRVO how low does this go? jeepers
0 replies
Adorno99 Oct 29, 11:40 PM
$CRVO who wants to see HC Wainwright reiterate their 25 dollar price target? 😄
1 replies
walker7782 Oct 29, 9:54 PM
$CRVO While early trial data was known, today’s formal peer-reviewed publication confirmed the Phase 2b primary endpoint miss. Today's PR also revealed CervoMed cannot fund Phase 3 alone and is seeking a partner, triggering institutional dumping and a liquidity vacuum on financing risk. Institutions are not jumping in, they jumped out. Big pharma won’t touch this without significant contributions from CRVO which means dilution for sure. So yes it tanked on “old data” but this was a full picture confirmation. If it was just a random journal publishing old news then it wouldn’t drop this hard. There is no institutional support and the dead cat bounce fell off hard. This wasn’t a drop on trial data so much as it was on a lack of financial stability.
2 replies
Orlandotrader Oct 29, 8:13 PM
$CRVO accurate. The primary endpoint of the Phase 2b RewinD-LB trial (change in the Clinical Dementia Rating Scale - Sum of Boxes, or CDR-SB) was missed in the initial 16-week placebo-controlled phase due to a drug product manufacturing issue that resulted in a defective drug batch (referred to as "Batch A") with decreased bioavailability and drug exposure. The announcement made on October 29, 2026, by CervoMed (NASDAQ: CRVO) is primarily a publication of existing data rather than entirely new trial results. Wow Mr market just slammed this on Old Data!!!!! Let’s see what New Data brings in November? CervoMed noted that actual new clinical data—specifically the 24-week biomarker data from its Phase 2a nfvPPA trial—is scheduled to be presented in November 2026 at the CTAD conference.
1 replies